EP0565708A1 - Vaccine against pathogens of mucosae using liposomes - Google Patents
Vaccine against pathogens of mucosae using liposomesInfo
- Publication number
- EP0565708A1 EP0565708A1 EP92924345A EP92924345A EP0565708A1 EP 0565708 A1 EP0565708 A1 EP 0565708A1 EP 92924345 A EP92924345 A EP 92924345A EP 92924345 A EP92924345 A EP 92924345A EP 0565708 A1 EP0565708 A1 EP 0565708A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pertussis
- omp
- liposomes
- vesicles
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- Pertussis is a severe respiratory disease which most commonly affects young infanis and prior to the 1930s was a major cause of child morbidity and mortality. Since then, large scale parenteral vaccination with heat-killed whole-cell preparations of Bordetella pertussis (the causative bacterium) and improved socio-economic conditions have greatly reduced the incidence of pertussis in the developed countries. However, In the past two decades there has been an upsurgence in the incidence of the disease following a reduced acceptance rate of the vaccine by parents mainly due to possible side effects which may be associated with pertussis vaccination. These range in severity from mild local reactions through persistent screaming to permanent brain damage. In some countries, doctors are reluctant to advise vaccination because of legal liability. In addition, vaccines can vary enormously between manufacturers and not all vaccine preparations are protective.
- Vaccines based on purified antigens namely detoxified pertussis toxin and filamentous haemagglutlnin, gave some protection in Swedish field trials but it is clear that these vaccines were contaminated with other antigens which may also play a role in protection. Thus a non-reactogenic highly efficacious vaccine is still not availaole.
- Alternative strategies thus need to be explored.
- pertussis The Incidence of pertussis in the developed countries has been largely reduced through large scale parenteral vaccination with heat-killed whole-cell preparations of B. pertussis.
- pertussis is still a world-wide problem due to a reduced acceptance rate of the present vaccine following heavy publicity of the possible side effects associated with vaccination [48], variation In efficacy associated with the manufacturing of vaccines [19], and the lack of vaccination programs in the underdeveloped countries where 95 % of the incidence of pertussis occurs [34].
- Phospholipid bilayered vesicles have been used as delivery systems for a wide variety of biologically active substances to specific tissues and more recently have been used as immunological adjuvants to enhance the immune response to several bacterial and viral antigens [17].
- liposomes as a delivery system to enhance the immunological response to B. pertussis surface antigens in the lungs.
- Bordetella pertussis is the etiologlcal agent of whooping cough, an infection of the human respiratory tract-
- the disease Is particularly severe In young children and may lead to
- pertussis have been considered for Inclusion in defined acellular vaccines and detoxified pertussis toxin (PT) and filamentous hemagglutinin (FHA) are prime candidates [29, 40].
- Conventional subunlt vaccines administered by parenteral route seem primarily elicit humoral Immunity; mucosal antibody responses are poor.
- B- pertussis bacteria infect through the respiratory tract mucosal membrane and specific immunoglobulin (lg) A Is elicited after natural infection [57].
- Such antibodies may well protectthe host from both colonization and disease. It would thus seem worthwhile to explore means of stimulating airways mucosal Immunity and to evaluate its utHlty In protecting from Infection and disease.
- Liposomes have been successfully used as delivery systems for drugs, antigens, hormones, and genetic material [17]. Promising results have also been obtained following immunization with antigens entrapped In liposomes; the oral [18, 43, 45, 61] and parenteral [4, 8, 10, 24, 25, 46, 49, 52] routes have been used for antigens of parasites [4, 24. 25.45. 49], virus [10, 38] and bacteria [8, 18, 43, 46, 52, 61]. Their potential as adjuvants have been demonstrated in several studies where the use of liposome-entrapped antigens resulted In protective immunity [4, 8. IB. 24. 25. 45. 49, 52], or at least cell-mediated [8] and humoral responses [10, 46].
- the adjuvantlcity of liposomes seems to depend on several factors Including vesicle size and structure, lipid constitution, surface charge, antigen localization, the animal species Immunized, route of immunization, and the distribution and number of lamellae.
- the association of orally administered antigens with liposomes enhance their absorption, targeting them to processing cells, and favors their presentation to T cells and uptake into regional lymphnodes. This process improves the induction of humoral, secretory and cell mediated immune responses [1, 2, 17. 58].
- the invention concerns a vaccine against pathogens of mucosae where the vaccine consists of a liposome delivery system or contains said delivery system as reactive component where the delivery system consists of lipid vesicles or contains same characterized in that the lipid vesicles contain at least one antigen of the pathogens of mucosae Incorporated into their outer membrane.
- the vaccine according to the invention can oe characterized in that the pathogen of mucosae is a strain of a species of Bordetella, especially B, pertussis, shigelia or streptococcus.
- the vaccine according to the invention can be characterized
- the antigen is a preparation of the outer membrane protein (OMP) of Bordetella pertussis
- the vaccine according to the invention can be characterized In that the antigen is a
- LPS lipopotysaccharide
- the vaccine according to the invention can be characterized in that the antigen is filamentous haemaglutinin and/or pertussis-toxin of Bordetella pertussis.
- the vaccine according to the Invention can be characterized In that both a preparation of the outer membrane protein (OMP) and a lipopotysaccharide (LPS) as well of Bordetella pertussis are contained as antigen. Further, the vaccine according to the invention can be characterized in that the vaccine according to lipid-vesicles are small multilamelar phospholipid-vesicles based on soybean.
- the Invention concerns a process for the preparation of a vaccine according to the Invention, characterized in that the antigen or the antigens are incorporated by means of the solvent dilution microcarr ⁇ er technique into the lipid-vesicles.
- LPS Lipopolysaccharide
- OMP outer-membrane protein
- mice After oral or Intra-nasal vaccination of mice with the coated liposomes, antigen-specific antibody responses were detected in lung washes.
- the OMP-coated liposomes were significantly more effective in inducing an Immune response than the OMP preparation alone. Responses were highest when mice were given a booster 30 days after primary immunisation. The maximum response occurred 20 days after the booster but specific antibody could still be detected 75 days after secondary immunisation.
- liposome antigen delivery system has potential in stimulating secretory antibody responses which may be necessary to effectively protect against infection from B. pertussis and that it should also be applicable to the delivery of a variety of candidate protein and /or LPS antigens from B. pertussis.
- liposomes have been used previously to elicit in-vivo antibody responses there are no reports of intra-nasal immunization or lung antibody responses following oral administration. This is of some importance since all present day whopping cough vaccines are administered parenterally and it is possible that this is insufficient to stimulate the mucosal immune system required as first line defense against colonization and subsequent infection. Indeed, some epidemiological evidence suggests that current vaccines protect more against the disease than against infection. Oral or intra-nasal administration of antigens may not only give better protection but may also circumvent the side reactions associated with parenteral vaccination such as the endotoxin shock due to small quantities of free LPS contaminating preparations of protein antigens. Our results show that liposome incorporated LPS does not result in endotoxin shock presumably by preventing insertion of lipidA portion of LPS into host cell membranes.
- Such a delivery system may also be applicable to vaccinate against other bacterial pathogens that gain entry into the animal host via the mucosal route i.e. primarily the lungs or the intestinal tract.
- Mice were orally vaccinated with liposome-entrapped filamentous hemagglutinin (FHA) and detoxified pertussis toxin (PT) of Bordetella pertussis.
- FHA- and PT-specific immunoglobulin (Ig) G was detected in serum, and both IgG and IgA In lung washes following the Immunization.
- Antibody titres obtained in mice immunized with encapsidated antigen were significantly higher than those In mice immunized with unencapsidated FHA and PT, which demonstrated the adjuvanticity of the liposome carrier.
- the results indicate the potential usefulness of this approach to elicit Immune responses against FHA and PT (and perhaps other pertussis antigens) in humans and its possible utility in large scale vaccination to protect both against B. pertussis infection and disease.
- Uncoated vesicles (A) and OMP-coated vesicles (C) were negatively stained with 4 % uranyl acetate; arrows indicate the multilamellar layers.
- B (uncoated vesicles) and D (OMP-coated vesicles) show vesicles after unidirectional metal-shadowing.
- OMP-coated vesicles were incubated with anti-OMP antibodies followed by Protein A-gold complexes (E, unstained vesicles; F, after metal shadowing); the gold particles (indicated by arrows) indicate the OMP material located at the outer surface of the OMP vesicles.
- OMP-coated vesicles were incubated with preimmune Immunoglobulin followed by protein A-gold complexes (G) or with the protein A-gold complexes alone (H); no labeling of the OMP-coated vesicles was detectable. Bars represent 0.2 m.
- LPS-coated vesicles 1 , LPS extracted from B. pertussis, 2, uncoated vesicles, 3. LPS coated vesicles.
- Electron microscopic examination of PT-coated liposomes PT-coated liposomes negatively stained with 4 % uranyl acetate, pH 4.5 (A); incubated with polyclonai anti-PT antibodies and protein A-gold complexes, metal-shadowed (B); control experiment, incubated with preimmune serum followed by protein A-gold complexes and metal-shadowed (C); post-embedding labeling, incubated with polyclonal anti-PT antibodies and protein A-gold complexes (D).
- G gold-particle; bars represent 0.1 um.
- B. pertussis D300421 (serotype 1.2.3) [31 was grown on Bordet Gengou base (Difco) with 1 % (v/v) and 15 % (v/v) defibrinated horse blood.
- B. pertussis was grown in Modified Homibrook medium [66].
- the top aqueous layer was removed and centrlfugated at 10,000 ⁇ g for 10 min to remove debris.
- the iipopoiysaccharide (LPS) was precipitated by the addition of two volumes of ice cold acetone and Incubation overnight. The precipitate was collected by centrifugation at 10,000 ⁇ g f or 1 o min at 4 oC and washed with 70 % acetone. The dried pellet was resuspended in 20 ml distilled water and
- the envelopes were then resuspended In 20 ml 2 % trlton X-100, 7.5 mM MgCl 2 , 50 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesul.onic acid) pH 7.4, allowed to stand for 1 h on ice. centrifuged at 100.000 ⁇ g for 1 h and washed once in the same buffer. The OMP preparation was then washed twice with distilled water. Protein concentrations were determined using a modification of the Lowry method [31].
- Lyphazome a proprietary form of small multilameiar phospholipid vesicles, were prepared containing
- mice Four to five week old female Balb/c mice were immunised in groups of five. Mice immunised intranasaily were anaesthetized by ether and 50 ul of vaccine dilution, in PBS. was deposited on the external nares and allowed to be enhaled. For mice immunised orally, vaccine was diluted appropriately in PBS and an equal volume of 3 % sodium bicarbonate In PBS (pH 8.0) was added just prior to immunisation to neutralise gastric acidity. Mice, deprived of water for 6 - 8 h, were gently fed with 50 ul. Unless otherwise stated, mice were immunised on days 1 and 4 and given a booster on day 30.
- PBS pH 8.0
- One dose consisted of 4 ulg protein for OMP-coated vesicles, and 15 ug dry weight for LPS-coated vesicles and uncoated vesicles.
- Mice were killed ten days after booster, unless otherwise stated, by cervical dislocation and bled from the brachial artery.
- Lung washes were obtained by cannulating the trachea with a syringe and filling and emptying the lungs four times with 0.7 ml ice cold PBS with 0.1 mM PMFS. From each mouse about 0.5 ml was recovered, centrifugated at 4 oC at 10,000 ⁇ g for 10 min to remove debris and stored at -20 oC.
- OMP preparation was emmulsified at a ratio of 1 :1 with Freunds incomplete adjuvant in a final volume of 1 ml and a three month Chinchilla rabbit was injected subcutaneously and Intramuscularly on day 1 (200 ug). day 30 (100 ug) and day 40 (100 ug). The rabbit was killed on day 50 and Immunoglobulin was purified from the obtained serum by protein A-sepharose CL4B chromatography.
- Proteins and LPS were electrophoretizally separated by sodium dodecyl sulphate polyacrylamide gel electrophoresls (SDS-PAGE) as previously described [30]. Proteins were stained by commassie blue and LPS by silver staining [59]. Western blotting was carried out as previously described [5]. Briefly proteins were transferred to nitrocellulose using a semi-dry transfer cell with 25 mM
- Microtitre plates (Nunc Maxisorp) were coated overnight at 4 °C with either OMP In 0.1 M NaHCO 3 pH 9.6 (5 ug in 50 ul per well), or LPS In 50 mM Tris HCI pH 9.6, 20 mM MgCl 2 (1 mg in 50 ul per well). The plates were washed and blocked with 10 % fetal calf serum (FCS) in PBS (100 ul per well) for 1 h at 37 °C. After washing, plates were incubated with various dilutions of serum or lung washes in 10 % FCS in PBS (50 ul per well) for 1 h at 37oC.
- FCS fetal calf serum
- Plates were washed and 50 ul (per well) of peroxidase conjugated goat anti-mouse IgA oranti IgG diluted 1 in 1000 in 10 % FCS In PBS was added. Plates were Incubated as before and after washing plates were developed by addition of 50 ul (per well) of substrate (0.25 M citric acid.0.25 M Na 2 HPO 4 . 0.0015 % H 2 O 2 .0 3 mg ml -1 O phenyl-diamine dihydrochioride). After 30 min at room temperature, the reaction was stopped by the addition of 50 ul of 0.25 M H 2 SO 4 and the A 490 was determined using a Blorad model 3550 microplate reader.
- results refer to the average values obtained from samples of 5 mice and an ELISA unit refers to the A 490 multiplied by the appropriate dilution factor after subtraction of background values obtained from mice not Immunised Undiluted lung washes and serum samples (diluted 1 in 50) from control mice gave essentially null readings.
- Uncoated and OMP-coated vesicles were negatively stained with 4 % aqueous uranyl acetate. pH 4.5, according to Valentine et al. [60].
- For metal-shadowing the two vesicle samples were absorbed onto freshly ptepared formvar covered nickel grids, washed with distilled water, air-dried and unidirectionally metal-shadowed with platinum (20 ° angle).
- Uncoated and OMP-coated vesicles were absorbed onto freshly prepared collodium covered nickel grids and carefully washed with distilled water. After being air-dried at room temperature the grids were treated with purified antibodies (100 ug lgG protein ml ) for 30 min at room temperature- Unbound antibodies were removed by a mild spray of PBS (0.1 M potassium phosphate, 0.15 M NaCI. pH 6.9) from a plastic bottle. The bound antibodies were made visible for electron microscopy by incubating the grids on drops of protein A-gold complexes (10 nm gold particle size and A 520 of 0.03) for 10 min at room temperature.
- PBS 0.1 M potassium phosphate, 0.15 M NaCI. pH 6.9
- the OMP-coated vesicles and the OMP preparation were analysed by SDS-PAGE (fig. 1) and found to contain essentially the same proteins Indicating that the incorporation technique did not select preferentially for specfic proteins. No proteins were detected in the uncoated vesicle preparation (results not shown). Electron microscopy of the uncoated and OMP-coated vesicles revealed that both vesicles were multilamellar and varied in size from 0.2 to 2 um (fig. 2A-D).
- the OMP-coated vesicles were different in morphological appearance when compared with the uncoated vesicles; due to incorporation of OMP, the OMP vesicles exhibited blebs (fig. 2D). Incubation of such vesicles with anti OMP antibodies resulted in an intense labeling of the vesicles (fig. 2E and F) demonstrating the location of the OMP material on the outer surface of the vesicles. In control experiments no labeling was observed (fig. 2G and H).
- mice immunised with OMP-coated vesicles were vaccinated intranasally with OMP-coated vesicles and the OMP preparation used to coat the vesicles, at the same protein concentration.
- OMP-coated vesicles the IgA and IgG titres in the lung washes were approximately 4 fold higher than for mice immunised with the OMP preparation (fig 3).
- the serum IgG title tor mice immunised by OMP-coated vesicles was about twice that for mice immunised by the OMP preparation. Mice immunised with uncoated vesicles showed no immune response to OMPS (results not shown).
- mice were sacrificed at various time intervals after the 30 day booster (fig. 5). The maximum IgA and IgG response both occurred 20 days after the booster but specific immunoglobulin could still be detected in the lungs after 75 days.
- Vesicles coated with OMP or LPS were shown to be effective in inducing a secretory and systemic immune response to these antigens.
- a secretory IgA response against LPS could only be detected after immunisation with the OMP-coated vesicles and not the LPS-coated vesicles.
- protein antigens In the OMP preparation had had an adjuvant effect in stimulating an IgA response.
- protein antigens are required for the Hdper T-cell presentation that mediates B-cell Isot ⁇ pe switching directly from IgM to IgA [54].
- Mice immunised with OMP vesicles gave secretory antibody titres about four fold higher than for mice immunised with the OMP preparation.
- GALT gut-associated lymphoid tissue
- BALT bronchus-associated lymphoid tissue
- CMI cell-mediated Immunity
- the liposome delivery system which enhanced antibody stimulation to these antigens, could be used to incorporate purified surface antigens such as filamemous haemagglutinin, pertussis toxin, or the 69 kd OMP associated with virulence, which have been shown to be protective in mouse models [671- The soya bean lipid source used to manufacture these liposomes is relatively cheap and therefore attractive for large-scale vaccine production.
- mice immunization Five to six week old female BALB/c mice (Charles River. Ml. Italy) were orally immunized In groups of five and caged separately according to the following protocol: group a. liposome-entrapped FHA; group b. liposome-entrapped PT; group c, liposome-entrapped FHA and liposome-entrapped PT; group d, free FHA; group e. free PT; group f, free FHA and PT; a control group was Immunized using uncoated liposomes.
- the vaccination regime was one dose of protein (4 ug) on day 0 and 4, followed by a booster of an identical dose on day 30-
- Mice that had been deprived of water for 6 - 8 h were gently fed with 50 ul of vaccine diluted in PBS and an equal volume of 3 % sodium bicarbonate In phosphate-buffered saline (PBS; NaCI [8.0 g liter -1 ], KCI [2.0 g liter -1 ], Na 2 HPO 4 .2H 2 O [2.0 g liter -1 ], KH 2 PO 4 [2.0 g liter -1 ) (pH 8.0), which was added Immediately before to neutralize gastric acidity. The animals were sacrificed 10 days after the booster and the samples were collected.
- mice Sacrificed mice were exsanguinated by cutting the brachial artery, and the collected serum was separated and stored at -20 oC.
- Lung washes were collected by pertracheal cannulation and gentle washing with 0.7 ml of ice cold PBS containing 2 mM phenyl-methane-sulfonylfiuoride as protease Inhibitor.
- About 0.5 ml of lung wash was recovered from each mouse, centrifuged at 4 °C at 10.000 ⁇ g for 5 min to remove debris and stored at -20 oC.
- ELISA enzyme-linked immunosorbent assays
- the plates were again washed and then developed by the addition of 100 ul per well of the substrate solution (10 mg/ml pnitrophenyiphosphate, disodlum salt, in d ⁇ ethanolamine buffer pH 9.8). After 30 min at room temperature, the reaction was stopped by the addition of 50 ul Of 3.0 M NaOH and the A 4D5 was determined with a TItretek Multlskan MCC microplaie reader (Flow). All samples were processed simultaneously on the same day, each serum or lung wash sample was individually assayed and antigen-free liposome-immunlzed mouse serum or lung washes were used as the blank for the ELISA readings. Results are expressed as mean values of each immunization group; standard deviations represent variations between individual mouse samples in each group.
- uncoated or antigen-coated liposomes were absorbed onto freshly prepared collodfum covered 300 mesh nickel grids and carefully washed with distilled water. After being air-dried at room temperature the grids were treated with protein A purified anti-FHA or PT polyclonai or monodonal antibodies (1.25 ug IgG protein ml -1 ) for 60 min at room temperature. Unbound antibodies were removed by a mild spray of PBS (pH 6.9) from a plastic bottle. The bound antibodies were made visibie for electron microscopy by incubating the grids on drops of protein A-gold complexes ( 10 nm gold particle size, A 520 of 0.01) for 15 mln at room temperature.
- protein A-gold complexes 10 nm gold particle size, A 520 of 0.01
- the grids were rinsed with PBS containing 0.01 % Tween 20 followed by distilled water. After being air-dried the grids were unidirectionally metal-shadowed with platinum (15 'angle) or examined without metal-shadowing. In control experiments, the samples were either treated with purified preimmune serum or with protein A-gold complexes alone. For post-embedding labeling the pertussis toxin liposomes were embedded according to the progressive lowering of temperature method using Lowicryl K4M resin and applying the labeling protocol as described [64]. Samples were examined with a Zeiss electron microscope EM lOB at an acceleration voltage of 80 kV and at calibrated magnifications.
- Size determination of liposomes containing FHA and PT Size analysis studies of the FHA and PT coated liposomes were performed using a Coulter Counter model N4M PT. The mean diameter of blank, and FHA or PT coated liposomes were 227 nm (95 % limits 211 to 243 nm), 236 nm (95 % limits 2T9 to 253 nm), and 244 (95 % limits 226 to 262 nm), respectively. These data demonstrate that the entrapment of FHA and PT Into the liposomes does not significantly affect their average diameter.
- the FHA-coated and PT-coated liposomes exhibit a different morphological appearatlce when compared with the uncoated liposomes (compare Fig.9 A and B, Fig.9 A and Fig.10 A) Most probably due to the incorporation of FHA and PT into the liposomes.
- Incubation of the FHA-coated liposomes with anti-FHA polyclonai or monoclonal antibodies followed by protein A-gold complexes resulted in an intensive labeling pattern on the surface of the FHA-liposomes (Fig, 9 D and E). Incubation with monoclonal antibodies revealed less labeling (data not shown).
- the processing of antigens administered by oral and parenteral routes differs regarding anligenic specificity and Ig class profile [2, 6, 27, 58], IgA responses being typical of oral vaccination.
- the specialized M cells which cover the Peyer's patches pass antigenic material to lymphocytes below the epithelium, where the processed antigens are presented to IgA-precursor B cells. These B cells travel via the lymphatic system to the different mucosae and then give rise to IgA secreting plasma cells. T lymphocytes may also acquire their homing pattern in the Peyer's patches [58].
- Humoral and cellular responses following parenteral immunization do not always correlate [44).
- cellmediated immune responses are believed to be important in vivo for protection against whooping cough disease [7, 14]. As liposomes are known to induce cell-mediaied immunity, it will be of interest to determine whether the delivery systems used in this study induce cell-mediated responses to FHA and PT in addition to the documented antibody responses.
- liposomes as delivery system for subunit vaccines to induce immune responses distal to the site of entry are very promising.
- the oral route may reduce or eliminate the most frequent local side effects associated with whooping cough vaccines, then adjuvanticlty may increase both coll mediated and humoral immune responses.
- Liposomes are chemically stable, simple to manufacture and biodegradable; toxicity was not reported after using liposomes in phase I and II trials [1 , 17].
- the inexpensive raw materials used to produce the liposomes will contribute to reduced production costs.
- the oral administration of vaccines is in any case associated with a major cost-saving vis-a-vis parenteral vaccination and is a key aspect of major vaccination programs, particularly in rural settlings where the health care delivery is very expensive. TABLE 1. Antibody titres to OMP of B. pertussis in mouse lung washes after oral and Intranasal administration of OMP-coated vesicles.
Abstract
Des préparations contenant des lipopolysaccharides (LSP) et des protéines de membrane externe (OMP) de Bordetella pertussis ont été incorporées à des liposomes composés de phospholipidis dérivés de fèves de soja. Après vaccination orale ou intranasale de souris avec ces liposomes enrobés, on a détecté des réponses sous forme d'anticorps spécifiques présents dans les lavages de poumons. On a cependant pu détecter une réponse aux LPS prenant la forme d'IgA spécifiques seulement après une immunisation pratiquée avec des liposomes enrobés d'OMP et non pas avec ceux enrobés de LPS, ce qui laisse supposer une activité adjuvante conférée par les protéines. Les liposomes enrobés d'OMP se sont montrés significativement plus efficaces que la seule préparation d'OMP pour induire une réponse immunitaire. Les réponses les plus marquées sont apparues quand les souris ont bénéficié d'un rappel 30 jours après l'immunisation primaire. La réponse maximum est survenue 20 jours après ce rappel mais on a encore pu détecter des anticorps 75 jours après l'immunisation secondaire. De tels résultats semblent indiquer que ce système de vecteur des antigènes recourant à des liposomes offre un certain potentiel pour stimuler des réponses sous forme de sécrétion d'anticorps, ce qui peut se révéler nécessaire pour conférer une protection efficace contre les infections dues à B. pertussis.Preparations containing lipopolysaccharides (LSP) and outer membrane proteins (OMP) from Bordetella pertussis have been incorporated into liposomes composed of phospholipidis derived from soybeans. After oral or intranasal vaccination of mice with these coated liposomes, responses were detected in the form of specific antibodies present in the lung washes. However, a response to LPS taking the form of specific IgA could only be detected after immunization carried out with liposomes coated with OMP and not with those coated with LPS, which suggests an adjuvant activity conferred by proteins. OMP-coated liposomes have been shown to be significantly more effective than the preparation of OMP alone in inducing an immune response. The most marked responses appeared when the mice received a booster 30 days after the primary immunization. The maximum response occurred 20 days after this booster, but antibodies could still be detected 75 days after the secondary immunization. Such results suggest that this vector system of antigens using liposomes offers some potential for stimulating responses in the form of antibody secretion, which may be necessary to provide effective protection against B. infections. pertussis.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4136553A DE4136553A1 (en) | 1991-11-06 | 1991-11-06 | Vaccine against mucous membrane exciter and manufacturing process |
DE4136553 | 1991-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0565708A1 true EP0565708A1 (en) | 1993-10-20 |
EP0565708A4 EP0565708A4 (en) | 1994-03-15 |
Family
ID=6444214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19920924345 Withdrawn EP0565708A4 (en) | 1991-11-06 | 1992-11-05 | Vaccine against pathogens of mucosae using liposomes. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0565708A4 (en) |
JP (1) | JPH06507420A (en) |
DE (1) | DE4136553A1 (en) |
WO (1) | WO1993008834A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08507077A (en) * | 1993-02-26 | 1996-07-30 | ファウンティン、ファーマスーティカルズ、インク | Vaccine delivery system and storage stable precursor solution for remote encapsulation of active ingredients |
GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
DE19703437A1 (en) * | 1997-01-30 | 1998-08-06 | Luitpold Pharma Gmbh | Mixtures of outer membranes and / or cell walls of bacteria for oral immunization against mucosal infections |
US6749831B1 (en) | 1997-05-16 | 2004-06-15 | Medical Defense Technology, Llc | Vaccine against lipopolysaccharide core |
SI1031347T1 (en) * | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
WO2007132790A1 (en) * | 2006-05-12 | 2007-11-22 | National University Corporation Hokkaido University | Liposome having lipid membrane containing bacterial cell component |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7532327B2 (en) * | 2004-09-17 | 2009-05-12 | Jmar Research, Inc. | Systems and methods for detecting scattered light from a particle using illumination incident at an angle |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
US4199565A (en) * | 1979-03-26 | 1980-04-22 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
CA1340241C (en) * | 1988-06-08 | 1998-12-15 | Fountain Pharmaceuticals, Inc. | Method for marking solvent dilution microcarriers |
WO1990001948A1 (en) * | 1988-08-25 | 1990-03-08 | The Liposome Company, Inc. | Influenza vaccine and novel adjuvants |
NZ230424A (en) * | 1988-08-25 | 1992-05-26 | Liposome Co Inc | Liposomal composition comprising an externally disposed antigen |
NL9000207A (en) * | 1990-01-29 | 1991-08-16 | Duphar Int Res |
-
1991
- 1991-11-06 DE DE4136553A patent/DE4136553A1/en not_active Withdrawn
-
1992
- 1992-11-05 JP JP5508757A patent/JPH06507420A/en active Pending
- 1992-11-05 EP EP19920924345 patent/EP0565708A4/en not_active Withdrawn
- 1992-11-05 WO PCT/US1992/009591 patent/WO1993008834A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7532327B2 (en) * | 2004-09-17 | 2009-05-12 | Jmar Research, Inc. | Systems and methods for detecting scattered light from a particle using illumination incident at an angle |
Non-Patent Citations (1)
Title |
---|
See also references of WO9308834A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE4136553A1 (en) | 1993-05-13 |
EP0565708A4 (en) | 1994-03-15 |
WO1993008834A1 (en) | 1993-05-13 |
JPH06507420A (en) | 1994-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960003378B1 (en) | Vaccine preparation | |
Orr et al. | Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models | |
Mallett et al. | Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection | |
Shahin et al. | Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection | |
US20050260225A1 (en) | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens | |
WO1993021950A1 (en) | Vaccine compositions for mucosal delivery | |
US20100255033A1 (en) | Non-toxic double mutant forms of pertussis toxin as adjuvants | |
de Oliveira Santos et al. | Evaluation of intranasal and subcutaneous route of immunization in neonatal mice using DODAB-BF as adjuvant with outer membrane vesicles of Neisseria meningitis B | |
US8758763B2 (en) | Archaeal polar lipid aggregates for administration to animals | |
Guzman et al. | Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid | |
Knight et al. | Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis | |
EP0565708A1 (en) | Vaccine against pathogens of mucosae using liposomes | |
US6660261B1 (en) | Bordetella strain expressing the FHA hybrid, liposomes and vaccines | |
Brownlie et al. | Stimulation of secretory antibodies against Bordetella pertussis antigens in the lungs of mice after oral or intranasal administration of liposome-incorporated cell-surface antigens | |
Jiskoot et al. | Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes | |
Mirchamsy et al. | Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections | |
US20070259007A1 (en) | Lactoferrin: an adjuvant for vaccines | |
WO2000023107A1 (en) | Vaccine preparations containing attenuated toxin | |
Faure et al. | Use of bacterial ribosomal immunostimulators in respiratory tract infections | |
Pérez et al. | Passive protection of serum from volunteers inoculated with attenuated strain 638 of Vibrio cholerae O1 in animal models | |
EP1578443B1 (en) | Compositions comprising antigen-complexes, method for making same as well as methods of using the antigen-complexes for vaccination | |
Lowell et al. | Proteosome™ technology for vaccines and adjuvants | |
Gebara et al. | Adjuvant and immunogenic activities of the 73 kDa N-terminal α-domain of BrkA autotransporter and Cpn60/60 kDa chaperonin of Bordetella pertussis | |
WO2013134656A1 (en) | Induction of th17 immune response | |
Kalambaheti et al. | CpG DNA, Liposome and Refined Anti-gen Oral Cholera Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930803 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 39/10 |
|
17Q | First examination report despatched |
Effective date: 19970901 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990527 |